FDA & Government News

FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

Secukinumab becomes the only interleukin-17A inhibitor approved for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.

Share

The FDA has approved secukinumab (Cosentyx) for pediatric patients aged 12 and older with moderate to severe hidradenitis suppurativa (HS). This biologic therapy uniquely inhibits interleukin-17A, marking the first new treatment option in nearly a decade for adolescents suffering from this chronic inflammatory skin condition. HS often starts around puberty, and many patients endure delayed diagnosis for up to 10 years. The approval is based on data from adult studies and pediatric modeling, providing a significant advancement in treatment choice for affected youths.

Original Source(s)

FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

  • by Kathryn Wighton

  • March 13, 2026

Related Content

Older RSV Hospitalization Linked to Pneumonia

Large Swedish cohort study finds children hospitalized for respiratory syncytial virus at older ages have greater risk of subsequent bacterial pneumonia

More Pediatric ER Visits for Tooth Pain

Dentists link rising pediatric ER visits to workforce shortages, worsening oral hygiene, and policy shifts that could further limit preventive care.

Major Food Allergy Risks Clarified

Early allergic conditions and delayed food introduction emerge as the strongest predictors of food allergy by age six